SAN DIEGO, March 18, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced the appointment of Gina Ford, RPh, MBA, as Vice President, Corporate Strategy and Commercial Planning.
“Crinetics is pleased to welcome Gina to the management team, where she brings 20 years of life sciences and pharmaceuticals experience, including leadership roles in commercial planning and corporate development,” said Scott Struthers, Ph.D., Founder and Chief Executive Officer of Crinetics. “Importantly, her endocrinology experience, which included the commercial leadership of a drug to treat acromegaly and neuroendocrine tumors, should prove invaluable as we advance our novel therapeutics for rare endocrine diseases and endocrine-related tumors through development to commercialization.”
Ms. Ford joins Crinetics from One Joule, LLC a commercial and corporate strategy consulting company she founded, where she provided biopharmaceutical clients with strategic advice on corporate, commercial, marketing and global market access strategy. She served as Vice President of Commercial Strategy at AcelRx Pharmaceuticals where she was instrumental in developing the global commercial strategy for AcelRx’s products.
Prior to forming One Joule, Gina served as Head of Endocrinology with Ipsen Pharmaceuticals, where she led the endocrine franchise through management of sales, marketing, medical, market access, finance, analytics, and project management. She also served leadership roles at Solstice Neurosciences and Elan Pharmaceuticals. Ms. Ford earned a B.S. in Pharmacy at Southwestern Oklahoma State University and an MBA from Capella University.
About Crinetics Pharmaceuticals
Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company’s lead product candidate, CRN00808, is an oral nonpeptide somatostatin agonist for the treatment of acromegaly, an orphan disease affecting more than 25,000 people in the United States. The company is also developing other oral nonpeptide somatostatin agonists for neuroendocrine tumors and hyperinsulinism, as well as an oral nonpeptide ACTH antagonist for the treatment of Cushing's disease. Crinetics was founded by a team of scientists with a track record of endocrine drug discovery and development. Please visit www.crinetics.com for more information.
Chief Financial Officer
Robert H. Uhl
Source: Crinetics Pharmaceuticals, Inc.